Oral vinorelbine: a narrative review
Authors:
- Carole FarrellCFCarole Farrell
- Victoria HarmerVHVictoria Harmer
- Mark FoulkesMFMark Foulkes
- Tom AllumTATom Allum
- 8 March 2018
- journal article
- research article
- Published by Royal College of Nursing in Cancer Nursing Practice
- Vol. 17 (2) , 25-33
Abstract
The incidence of many cancers is increasing; coupled with a decline in mortality rates (Cancer Research UK 2017a) this translates to more people living with and beyond their cancer diagnosis. Cancer is generally viewed as a chronic condition and this is often true for many diagnosed with metastatic breast cancer (MBC). In advanced/metastatic disease, there is a greater emphasis on promoting patients’ quality of life, and oral treatments can have additional benefits for patients, such as ease of administration, potentially reduced toxicities and fewer hospital visits. Oral vinorelbine was licenced in 2006 for the treatment of non-small cell lung cancer and MBC. This paper provides a narrative review of evidence from clinical trials, outlining the development and clinical application of oral vinorelbine, including implications for clinical practice and patient care.Keywords
This publication has 53 references indexed in Scilit:
- Oral single-agent chemotherapy in older patients with solid tumours: A position paper from the International Society of Geriatric Oncology (SIOG)European Journal of Cancer, 2015
- Oral vinorelbine in the treatment of non-small-cell lung cancerExpert Opinion on Pharmacotherapy, 2014
- An evaluation of the pharmacokinetics and clinical use of vinorelbine for NSCLC treatmentExpert Opinion on Drug Metabolism & Toxicology, 2013
- Vinorelbine in Cancer TherapyCurrent Drug Targets, 2012
- Oral vinorelbine in metastatic breast cancer: A review of current clinical trial resultsCancer Treatment Reviews, 2012
- Phase II trial of single-agent oral vinorelbine in elderly (≥70 years) patients with advanced non-small-cell lung cancer and poor performance statusAnnals of Oncology, 2009
- International Guidelines for Management of Metastatic Breast Cancer: Combination vs Sequential Single-Agent ChemotherapyJNCI: Journal of the National Cancer Institute, 2009
- Chemotherapy and targeted agents for elderly women with advanced breast cancer.Recent Patents on Anti-Cancer Drug Discovery, 2008
- Management of Unresectable Stage III Non–Small-Cell Lung Cancer with Combined-Modality Therapy: A Review of the Current Literature and Recommendations for TreatmentClinical Lung Cancer, 2008
- Oral VinorelbineDrugs, 2007